nach oben

European Journal of Drug Metabolism and Pharmacokinetics

Erschienen in:

27.06.2023 | Original Research Article

Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats

verfasst von: Yuki Inoue, Yuki Sato, Hitoshi Kashiwagi, Shunsuke Nashimoto, Mitsuru Sugawara, Yoh Takekuma

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Therapeutic drug monitoring (TDM) is an effective tool for the management of patients who are administered linezolid. The use of saliva for TDM has potential advantages over the use of plasma; however, only a few reports have compared drug concentrations in the saliva and plasma. Moreover, there are no reports on the salivary concentration of tedizolid, an oxazolidinone antibiotic similar to linezolid. In the present study, the concentrations of tedizolid and linezolid in rat submandibular saliva were compared with those measured in the plasma.

Methods

Tedizolid (10 mg/kg, n = 6) and linezolid (12 mg/kg, n = 5) were administered via the rat tail vein. Submandibular saliva and plasma samples were collected for up to 8 h after the initiation of drug administration, and assayed for the concentrations of tedizolid and linezolid.

Results

A strong correlation was found between the saliva and plasma concentrations of tedizolid (r = 0.964, p < 0.001) and linezolid (r = 0.936, p < 0.001). The value of tedizolid maximum concentration of drug (C_max) was 0.99 ± 0.08 µg/mL in the saliva and 14.46 ± 1.71 µg/mL in the plasma. Meanwhile, the C_max of linezolid was 8.01 ± 1.42 µg/mL in the saliva and 13.00 ± 1.90 µg/mL in the plasma. According to these results, the saliva/plasma concentration ratios of tedizolid and linezolid in rats were 0.0513 ± 0.0080 and 0.6341 ± 0.0339, respectively.

Conclusions

Considering the correlation between saliva and plasma concentrations of tedizolid and linezolid, as well as the characteristics of saliva, the results of this study suggest that saliva is a useful matrix for TDM.

Nur mit Berechtigung zugänglich

Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759–67. https://doi.org/10.2147/DDDT.S164515.CrossRefPubMedPubMedCentral

Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47(12):3964–6. https://doi.org/10.1128/AAC.47.12.3964-3966.2003.CrossRefPubMedPubMedCentral

Kawasuji H, Tsuji Y, Ogami C, Kaneda M, Murai Y, Kimoto K, et al. Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients. Antibiotics (Basel). 2021;10(5):496. https://doi.org/10.3390/antibiotics10050496.CrossRefPubMedPubMedCentral

Shi C, Xia J, Ye J, Xie Y, Jin W, Zhang W, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):464–75. https://doi.org/10.1111/bcp.14965.CrossRefPubMed

Inoue Y, Takekuma Y, Miyai T, Kashiwagi H, Sato Y, Sugawara M, et al. Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia. Eur J Clin Pharmacol. 2023;79(3):415–25. https://doi.org/10.1007/s00228-023-03455-x.Advanceonlinepublication.CrossRefPubMed

Ferry T, Batailler C, Conrad A, Triffault-Fillit C, Laurent F, Valour F, et al. Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug-resistant Staphylococcus epidermidis prosthetic-joint infection. Open Forum Infect Dis. 2018. https://doi.org/10.1093/ofid/ofy246.CrossRefPubMedPubMedCentral

Hall RG 2nd, Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Infect Drug Resist. 2015;8:75–82. https://doi.org/10.2147/IDR.S56691.CrossRefPubMedPubMedCentral

Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48(6):728–31. https://doi.org/10.1016/j.ijantimicag.2016.08.023.CrossRefPubMed

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–42. https://doi.org/10.1093/jac/dks153.CrossRefPubMed

10.

Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M, Iatdmct Antimicrobial Scientific Committee. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice A review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit 42 (1) 83-92

11.

Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015;61(8):1315–21. https://doi.org/10.1093/cid/civ501.CrossRefPubMed

12.

Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014;42(8):1275–84. https://doi.org/10.1124/dmd.113.056697.CrossRefPubMed

13.

Gentry-Nielsen MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2002;46(5):1345–51. https://doi.org/10.1128/AAC.46.5.1345-1351.2002.CrossRefPubMedPubMedCentral

14.

Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41(4):409–30. https://doi.org/10.1097/FTD.0000000000000643.CrossRefPubMed

15.

Idkaidek N, Arafat T. Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. Mol Pharm. 2012;9(8):2358–63. https://doi.org/10.1021/mp300250r.CrossRefPubMed

16.

Zyvox^® package insert, U.S Food & Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf. Accessed 21 February 2023.

17.

Hara S, Uchiyama M, Yoshinari M, Matsumoto T, Jimi S, Togawa A, et al. A simple high-performance liquid chromatography for the determination of linezolid in human plasma and saliva. Biomed Chromatogr. 2015;29(9):1428–31. https://doi.org/10.1002/bmc.3441.CrossRefPubMed

18.

Dai Y, Jiang S, Chen X, Han L, Zhang C, Yu X, et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J Clin Pharm Ther. 2021;46(3):807–13. https://doi.org/10.1111/jcpt.13359.CrossRefPubMed

19.

Nashida T, Sato R, Imai A, Shimomura H. Gene expression profiles of the three major salivary glands in rats. Biomed Res. 2010;31(6):387–99. https://doi.org/10.2220/biomedres.31.387.CrossRefPubMed

20.

Nezu A, Morita T, Nagai T, Tanimura A. Simultaneous monitoring of Ca²⁺ responses and salivary secretion in live animals reveals a threshold intracellular Ca²⁺ concentration for salivation. Exp Physiol. 2019;104(1):61–9. https://doi.org/10.1113/EP086868.CrossRefPubMed

21.

Xu S, Li C, Zhou H, Yu L, Deng L, Zhu J, et al. A study on acetylglutamine pharmacokinetics in rat blood and brain based on liquid chromatography-tandem mass spectrometry and microdialysis technique. Front Pharmacol. 2020;11:508. https://doi.org/10.3389/fphar.2020.00508.CrossRefPubMedPubMedCentral

22.

Yan J, He X, Feng S, Zhai Y, Ma Y, Liang S, et al. Up-regulation on cytochromes P450 in rat mediated by total alkaloid extract from Corydalis yanhusuo. BMC Complement Altern Med. 2014;14:306. https://doi.org/10.1186/1472-6882-14-306.CrossRefPubMedPubMedCentral

23.

The Japanese Pharmacopoeia 18th edition, general notices (Official from June 7, 2021).

24.

Parkin GM, McCarthy MJ, Thein SH, Piccerillo HL, Warikoo N, Granger DA, et al. Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model. Bipolar Disord. 2021;23(7):679–88. https://doi.org/10.1111/bdi.13128.CrossRefPubMedPubMedCentral

25.

Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia. 2011;52(2):258–63. https://doi.org/10.1111/j.1528-1167.2010.02751.x.CrossRefPubMed

26.

Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants Clin Pharmacokinet. 1999;36(6):453–70. https://doi.org/10.2165/00003088-199936060-00006.CrossRefPubMed

27.

Kim DY, Moon J, Shin YW, Lee ST, Jung KH, Park KI, et al. Usefulness of saliva for perampanel therapeutic drug monitoring. Epilepsia. 2020;61(6):1120–8. https://doi.org/10.1111/epi.16513.CrossRefPubMed

28.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3676–80. https://doi.org/10.1128/AAC.00558-13.CrossRefPubMedPubMedCentral

29.

Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med. 2004;42(11):1273–87. https://doi.org/10.1515/CCLM.2004.248.CrossRefPubMed

30.

Taylor R, Sunderland B, Luna G, Czarniak P. Evaluation of the stability of linezolid in aqueous solution and commonly used intravenous fluids. Drug Des Devel Ther. 2017;11:2087–97. https://doi.org/10.2147/DDDT.S136335.CrossRefPubMedPubMedCentral

31.

Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85(2):162–9. https://doi.org/10.1067/mpr.2001.113778.CrossRefPubMed

32.

Tatevossian A, Wright WG. The collection and analysis of resting rat saliva. Arch Oral Biol. 1974;19(9):825–7. https://doi.org/10.1016/0003-9969(74)90173-3.CrossRefPubMed

33.

Langman LJ. The use of oral fluid for therapeutic drug management: clinical and forensic toxicology. Ann N Y Acad Sci. 2007;1098:145–66. https://doi.org/10.1196/annals.1384.001.CrossRefPubMed

34.

Lamy E, Graça G, da Costa G, Franco C, E Silva FC, Baptista ES, et al. Changes in mouse whole saliva soluble proteome induced by tannin-enriched diet. Proteome Sci. 2010;8:65. https://doi.org/10.1186/1477-5956-8-65.

35.

Louro T, Simões C, Lima W, Carreira L, Castelo PM, Luis H, et al. Salivary Protein Profile and Food Intake: A Dietary Pattern Analysis. J Nutr Metab. 2021;2021:6629951. https://doi.org/10.1155/2021/6629951.CrossRefPubMedPubMedCentral

36.

Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–7. https://doi.org/10.1007/s10156-010-0182-1.CrossRefPubMed

37.

Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–33. https://doi.org/10.1093/jac/dkt133.CrossRefPubMed

38.

Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–33. https://doi.org/10.1016/j.clinthera.2009.10.017.CrossRefPubMed

39.

Daisho T, Kagami K, Yamazaki K, Ishiguro N, Endo T, Takahata M, et al. Therapeutic drug monitoring-enabled long-term use of linezolid for the successful treatment of refractory pyogenic spondylodiscitis without development of thrombocytopenia: A case report. J Orthop Sci. 2021;S0949–2658(21):384–5. https://doi.org/10.1016/j.jos.2021.11.018.CrossRef

40.

Yahya M, Saghir MZ. Empirical modelling to predict the refractive index of human blood. Phys Med Biol. 2016;61(4):1405–15. https://doi.org/10.1088/0031-9155/61/4/1405.CrossRefPubMed

41.

Roblegg E, Coughran A, Sirjani D. Saliva: An all-rounder of our body. Eur J Pharm Biopharm. 2019;142:133–41. https://doi.org/10.1016/j.ejpb.2019.06.016.CrossRefPubMed

Titel: Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats
verfasst von: Yuki Inoue
Yuki Sato
Hitoshi Kashiwagi
Shunsuke Nashimoto
Mitsuru Sugawara
Yoh Takekuma
Publikationsdatum: 27.06.2023
Verlag: Springer International Publishing
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 4/2023
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-023-00836-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats

Abstract

Background and Objective

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study

Hydrolytic Metabolism of Withangulatin A Mediated by Serum Albumin Instead of Common Esterases in Plasma

Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit

Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept

Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case